

August 14, 2026

Consolidated Financial Results for the Three Months Ended June 30, 2026 (Under Japanese GAAP)

Company name: Japan Animal Referral Medical Center (JARMeC)
 Listing: Tokyo Stock Exchange
 Securities code: 6039
 URL: <https://www.jarmec.co.jp>
 Representative: Hidehiro Hirao, Representative Director and President
 Inquiries: Masami Oe, Executive Director and Head of Corporate Administration
 Telephone: +81-44-850-1320
 Scheduled date to commence dividend payments: -
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2026 (from April 1, 2026 to June 30, 2026)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2026	1,644	11.6	349	35.0	347	34.6	239	33.0
June 30, 2025	1,473	17.8	258	73.3	258	71.2	180	75.0

Note: Comprehensive income For the three months ended June 30, 2026: ¥239 million [33.0%]
 For the three months ended June 30, 2025: ¥180 million [75.0%]

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2026	18.54	-
June 30, 2025	13.95	-

Note: 1. Quarterly net income per share after adjusted for potential shares is not shown because there are no potential shares.

2. On December 17, 2025, the Company conducted a share split at a ratio of 5 shares per share of common shares. Assuming that the stock split occurred at the beginning of the previous fiscal year, "quarterly net income per share" is calculated.

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
June 30, 2026	11,235	4,957	44.1
March 31, 2026	11,313	4,881	43.1

Reference: Equity
 As of June 30, 2026: ¥4,957 million
 As of March 31, 2026: ¥4,881 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	-	0.00	-	12.00	12.00
Fiscal year ending March 31, 2027	-				
Fiscal year ending March 31, 2027 (Forecast)		0.00		13.00	13.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Forecast of consolidated financial results for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending March 31, 2027	6,600	6.6	1,270	10.4	1,220	6.8	890	6.8	68.86

Note: Revisions to the earnings forecasts most recently announced: None

2. Since the Group manages its operations on an annual basis, the consolidated earnings forecast for the second quarter (cumulative) is omitted.

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes

Note: For details, see "2. Quarterly Consolidated Financial Statements and Key Notes (3) Notes on Quarterly Consolidated Financial Statements (Notes on Accounting Procedures Specific to the Preparation of Quarterly Consolidated Financial Statements)" are available.

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: Yes

(iv) Restatement: None

Note: For details, see "2. Quarterly Consolidated Financial Statements and Key Notes (3) Notes on Quarterly Consolidated Financial Statements (Notes on Changes to Accounting Estimates)" are available.

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2026	14,391,000 shares
As of March 31, 2026	14,391,000 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2026	1,466,240 shares
As of March 31, 2026	1,466,540 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Three months ended June 30, 2026	12,924,617 shares
Three months ended June 30, 2025	12,923,790 shares

Note: 1. The number of treasury shares at the end of the fiscal year and the number of treasury shares to be deducted for the calculation of the average number of shares during the period include the Company's shares held by the J-ESOP Trust Account.

2. On December 17, 2025, the Company conducted a share split at a ratio of 5 shares per share of common shares. Assuming that the stock split occurred at the beginning of the previous fiscal year, the "average number of shares during the period" is calculated.

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm:None

* Proper use of earnings forecasts, and other special matters

- The forward-looking statements, including forecasts of financial results, contained in these materials are based on information available to the Company and on certain assumptions deemed to be reasonable. Actual financial results may differ from the results anticipated in the statements due to various factors. Matters related to the above earnings forecasts are described in the attached document "1. Summary of Operating Results, etc. (3) Explanation of Forward-Looking Information such as Consolidated Earnings Forecasts."

Quarterly consolidated balance sheet

(Thousands of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and deposits	1,592,885	1,254,422
Accounts receivable - trade, and contract assets	367,284	395,044
Merchandise and finished goods	73,014	104,847
Raw materials and supplies	20,408	23,623
Other	66,334	65,080
Allowance for doubtful accounts	(8,959)	(10,112)
Total current assets	2,110,967	1,832,905
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	2,169,022	2,147,667
Tools, furniture and fixtures, net	1,715,682	1,817,679
Land	4,329,353	4,330,674
Other, net	4,645	15,402
Total property, plant and equipment	8,218,703	8,311,424
Intangible assets		
Goodwill	122,219	117,126
Trademark right	261,278	250,391
Software in progress	137,258	252,785
Other	34,566	30,568
Total intangible assets	555,322	650,871
Investments and other assets	428,995	440,574
Total non-current assets	9,203,022	9,402,871
Total assets	11,313,989	11,235,776

	As of March 31, 2026	As of June 30, 2026
Liabilities		
Current liabilities		
Accounts payable - trade	72,030	87,231
Accounts payable - other	324,234	185,619
Short-term borrowings	2,038,000	1,839,000
Current portion of long-term borrowings	644,099	681,107
Income taxes payable	239,135	122,621
Provision for bonuses	178,218	83,102
Other	242,216	417,594
Total current liabilities	3,737,934	3,416,275
Non-current liabilities		
Long-term borrowings	2,476,847	2,639,647
Provision for share awards	64,580	75,316
Retirement benefit liability	51,250	50,350
Deferred tax liabilities	57,836	54,277
Asset retirement obligations	43,849	41,978
Other	313	209
Total non-current liabilities	2,694,677	2,861,780
Total liabilities	6,432,612	6,278,055
Net assets		
Shareholders' equity		
Share capital	801,600	801,600
Capital surplus	720,405	720,405
Retained earnings	3,912,404	3,988,631
Treasury shares	(553,034)	(552,916)
Total shareholders' equity	4,881,376	4,957,720
Total net assets	4,881,376	4,957,720
Total liabilities and net assets	11,313,989	11,235,776

Quarterly consolidated statement of income

(Thousands of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Net sales	1,473,468	1,644,119
Cost of sales	910,422	942,767
Gross profit	563,045	701,351
Selling, general and administrative expenses	304,267	352,017
Operating profit	258,778	349,334
Non-operating income		
Rental income from buildings	6,031	6,031
Compensation income	-	8,250
Other	5,081	2,342
Total non-operating income	11,112	16,624
Non-operating expenses		
Interest expenses	8,813	16,692
Financing expenses	687	847
Loss on retirement of non-current assets	772	980
Other	1,526	9
Total non-operating expenses	11,799	18,530
Ordinary profit	258,091	347,428
Profit before income taxes	258,091	347,428
Income taxes	77,803	107,716
Profit	180,288	239,711
Profit attributable to owners of parent	180,288	239,711

Quarterly consolidated statement of comprehensive income

(Thousands of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Profit	180,288	239,711
Comprehensive income	180,288	239,711
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	180,288	239,711

(Notes on segment information, etc.)

Segment Information

Since the Group is a single segment of the veterinary healthcare-related business, the description is omitted.